AIA Group Ltd acquired a new stake in Karuna Therapeutics, Inc. (NASDAQ:KRTX – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 3,630 shares of the company’s stock, valued at approximately $1,149,000.
Other hedge funds have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its position in shares of Karuna Therapeutics by 349.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,363 shares of the company’s stock valued at $1,381,000 after purchasing an additional 3,392 shares during the period. SG Americas Securities LLC boosted its position in shares of Karuna Therapeutics by 598.2% in the 3rd quarter. SG Americas Securities LLC now owns 6,745 shares of the company’s stock valued at $1,141,000 after purchasing an additional 5,779 shares during the period. Hsbc Holdings PLC acquired a new stake in shares of Karuna Therapeutics in the 3rd quarter valued at about $2,029,000. New York Life Investment Management LLC boosted its position in shares of Karuna Therapeutics by 140.1% in the 3rd quarter. New York Life Investment Management LLC now owns 3,788 shares of the company’s stock valued at $641,000 after purchasing an additional 2,210 shares during the period. Finally, Deutsche Bank AG boosted its position in shares of Karuna Therapeutics by 16.4% in the 3rd quarter. Deutsche Bank AG now owns 51,584 shares of the company’s stock valued at $8,722,000 after purchasing an additional 7,282 shares during the period.
Insider Activity at Karuna Therapeutics
In related news, insider Stephen K. Brannan sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $318.34, for a total value of $1,591,700.00. Following the completion of the transaction, the insider now directly owns 42,604 shares of the company’s stock, valued at approximately $13,562,557.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 13.20% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on KRTX
Karuna Therapeutics Price Performance
KRTX opened at $329.83 on Friday. The business has a 50 day simple moving average of $324.58 and a 200-day simple moving average of $265.86. The stock has a market capitalization of $12.58 billion, a P/E ratio of -28.14 and a beta of 1.18. Karuna Therapeutics, Inc. has a 12 month low of $158.38 and a 12 month high of $329.99.
Karuna Therapeutics (NASDAQ:KRTX – Get Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($3.01) EPS for the quarter, missing the consensus estimate of ($2.65) by ($0.36). During the same quarter last year, the business earned ($2.22) earnings per share. Karuna Therapeutics’s quarterly revenue was down 100.0% compared to the same quarter last year. Research analysts anticipate that Karuna Therapeutics, Inc. will post -11.96 EPS for the current year.
Karuna Therapeutics Company Profile
Karuna Therapeutics, Inc, a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease.
Featured Stories
- Five stocks we like better than Karuna Therapeutics
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- MarketBeat Week in Review – 4/15 – 4/19
- The How and Why of Investing in Biotech Stocks
- Comprehensive Analysis of PayPal Stock
- Options Trading – Understanding Strike Price
- Intuitive Surgical Stock Can Trend Much Higher This Year
Receive News & Ratings for Karuna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karuna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.